CepTor Moves to Dismiss Xmark Lawsuit.

HUNT VALLEY, Md. -- CepTor Corporation, Inc. (OTCBB:CEPO), a development-stage biopharmaceutical company focusing on cell targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced today that it filed a motion to dismiss the complaint filed by Xmark Opportunity Fund,

In early July, CepTor was approached by Xmark with a demand, under a threat of litigation, that the Company purchase all of its shares at a premium to the market and reset its warrants. After rejecting Xmark's threats of suit as baseless and rejecting its related demands, Xmark filed suit. Xmark complained that the registration of its shares took too long so it did not have an opportunity to sell its stock, yet, to date, Xmark has not even attempted to convert its Series A Preferred Stock into sellable common stock.

William Pursley, Chief Executive Officer of CepTor said, "We believe Xmark's actions speak for themselves and that their lawsuit is wholly without merit, as reflected by our decision to immediately move for dismissal. Unfortunately, it is detrimental to Company shareholders as it diverts attention from the important research we are completing in preparation for the filing of our Investigational New Drug application (IND) for Myodur in Duchenne muscular dystrophy."

About CepTor

CepTor Corporation is a development-stage biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary, cell-targeted therapeutic products for the treatment of neuromuscular and neurodegenerative diseases with a focus on orphan diseases. The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. An orphan disease is defined in the United States as a serious or life-threatening disease that affects less than 200,000 people and for which no definitive therapy currently exists. CepTor Corporation seeks to create an efficient orphan drug platform by taking advantage of the legislative, regulatory and commercial opportunities common to these rare diseases. CepTor's primary efforts are currently being focused on moving its lead product, MYODUR, into phase I/II clinical trials for Duchenne muscular dystrophy. The Company's broad platform technology also includes the development of products for multiple sclerosis, retinal degeneration and epilepsy.

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement.